Synovial fluid proteome expression patterns segregate juvenile idiopathic arthritis patients


Link to publication record in Ulster University Research Portal

Published in:
Rheumatology

Publication Status:
Published (in print/issue): 01/01/2008

DOI:
10.1093/rheumatology/kem512

Document Version
Publisher's PDF, also known as Version of record

General rights
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk.
Results: Proliferation of T cells when co-cultured with adenosine-infected DC was inhibited both in healthy volunteers (alloigenic response) and samples from PB from children with JIA. In vitro only minor or no significant reduction in T cell proliferation was seen when T cells were from the synovial fluid compartment. The effect was not due to direct rAd infection of T cells.

Conclusions: We have shown that tolerogenic DC from synovial cells of children with arthritis can be generated in vitro. These DC were able to inhibit T cell proliferation when T cells were obtained from peripheral blood. Our data suggest that T cells from the joint were resistant to this suppression. The mechanisms of this resistance will be important to elucidate since this may provide new therapeutic targets for athero-distal disease.

Disclosure: The authors have declared no conflicts of interest.

87. THE USE OF AN AGE SPECIFIC NORMAL RANGE TO INCREASE DETECTION OF ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) ANTIBODIES AND RHEUMATOID FACTOR (RF) IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)
Neil Mo, Nick Amos, Anurag Negi and Jeremy Camilleri
Rheumatology, University Hospital of Wales, Cardiff, United Kingdom

Background: The presence of anti-CCP antibodies has been well established in adult Rheumatoid Arthritis patients and children with JIA. Current commercial ELISA kits use a reference ‘normal range’ derived from the adult population. Anti-CCP antibody testing is not currently used for diagnosis of JIA given the low sensitivity (reported detection rates of 4-10% in recent studies). The aim of this study is to demonstrate whether using a paediatric normal range for CCP and RF testing results in higher detection rates, which may increase the value of these tests in a clinical setting.

Methods: Samples were collected from 43 patients with JIA and 26 juvenile controls. Anti-CCP antibodies were detected using a combination of anti-CCP2 (Axiom-Shield), anti-CCP3 (Inova) and an in-house peptide (cfc-1-cyc Invitrogen). IgM RF and IgA RF were also measured in these samples by ELISA. The manufacturer’s normal range was compared with a normal range calculated from the 25th and 75th percentiles (with standard deviations from the mean).

Results: Measurement of anti-CCP2 antibodies in JIA identified 16% being positive using the manufacturer’s normal range. Sensitivity was increased to 23% in this assay using a normal range calculated from serum of juvenile controls. Using a combination of all 3 assays, the detection rate of anti-CCP antibodies was also 23% when an adult normal range was applied. However, this increased to 33% if the juvenile normal range was applied. 2 of the 26 juvenile controls tested positive using the combined kits. Screening for RF isoforms IgG or IgA identified 11 out of 42 (26%) JIA patients. 20 out of 43 (47%) JIA patients had autoantibodies to either anti-CCP or RF.

Conclusions: We have found that using a juvenile rather than an adult normal range from age-matched controls increased the detection rate of anti-CCP antibodies in JIA. This suggests that levels of anti-CCP antibody may change with age. However, in order to prove this, a large scale study using appropriate age-matched controls is needed.

88. SYNOVIAL FLUID PROTEOME EXPRESSION PATTERNS SEGREGATE JUVENILE IDIOPATHIC ARTHRITIS PATIENTS
David S. Gibson1, Sarah Blelock1, Jim Curry1, Sorcha Finnegan1, Adrienne Healy1, Caitliona Scaife2, Catherine McAllister1, Stephen Pennington2, Michael Dunn2 and Madeleine Rooney1
1Arthritis Research Group, Queen’s University Belfast, Belfast, United Kingdom and 2Proteome Research Centre, University College Dublin, Dublin, Ireland

Background: Synovial fluid (SF) is a potential source of novel biomarkers for many arthritic disorders involving joint inflammation, including Juvenile Idiopathic Arthritis (JIA). We first compared the distinctive protein expression patterns of local joint inflammation in SF with systemic profiles within matched plasma samples. Preliminary investigations were performed into whether local or systemic proteome “fingerprints” exist between oligoarticular, extended oligoarticular and polyarticular forms of this chronic juvenile disease.

Methods: In this study we analysed matched SF and plasma samples obtained from 10 newly diagnosed JIA patients (<6 months disease duration): 3 with oligoarticular arthritis, 3 extended oligoarticular and 4 polyarticular disease. Matched samples were taken at the initial inflammatory episode. We profiled the SF and plasma proteomes using a two-dimensional difference gel electrophoresis (DIGE) approach. Progenesis PG240 software analysis of plasma and SF gel scans was used to highlight proteins identified by mass spectrometry across the study group. Protein spots of interest were identified by matrix-assisted laser desorption ionization (MALDI-TOF) and confirmed by nanoelectrospray-ionisation mass spectrometry.

Results: 2D DIGE revealed 899 spots per gel within the pH 4–7 range for synovial fluid and plasma. Comparison of plasma and synovial gel scans, revealed a sub-population of 143 spots which predominates in synovial fluid or plasma. Hierarchical clustering based on the expression levels of a set of 54 proteins with at least two fold expression differences between the two body fluids segregates the synovial fluid from the plasma samples. Proteolytic fragments of anti-inflammatory proteins inter-alpha trypsin inhibitor, alpha-1 antitrypsin, transthyretin and apolipoprotein A-1 were identified. Principle component analysis of five different protein features could be used to segregate patients into clinical subgroups.

Conclusions: Synovial fluid and plasma proteomes can be used to segregate a homogeneous group of JIA patients into clinical subgroups. Such an approach could allow for the early identification of disease progression, and therefore enable earlier and more appropriate therapeutic intervention. Definition of protein profiles which discriminate clinical subgroups of arthritic disease may assist in the diagnosis of juvenile arthritis at an earlier stage than is currently possible.

Disclosure: The authors have declared no conflicts of interest.

89. STEROID USE IN THE MANAGEMENT OF ACUTE JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS - A NATIONAL SURVEY
Zoe L. McLaren and Michael W. Beresford
Institute of Child Health, Royal Liverpool Children’s Hospital (Alder Hey), on behalf of The UK JSLE Study Group, Liverpool University, Liverpool, United Kingdom

Background: Corticosteroids, along with cytotoxic and disease modifying agents, form the core of the every day management of JSLE (Juvenile Systemic Lupus Erythematosus). However this is not without significant side effects, particularly in children. There are no randomised controlled trials investigating the optimal steroid regime in JSLE and there is a paucity of evidence to draw upon, particularly in adult studies.

Methods: On behalf of the UK JSLE Study Group we issued a standardised questionnaire, designed to elucidate current practise in the prescription of steroids during induction of remission and treatment of flare of JSLE, defined as a typical child presenting with BILAG (British Isles Lupus Assessment Group) A disease. The questionnaire was sent to the lead paediatric & nephrologist in each UK tertiary centre involved the UK JSLE Study Group.

Results: 18/26 (69%) questionnaires were returned (8 nephrology; 10 rheumatology units) representing 3 centres.

Management of BILAG A at presentation:
All participants reported using pulsed intravenous methylprednisolone (IVMP) as the steroid treatment of choice for induction of remission at presentation. The most widely used dosing was 30 mg/kg (n = 11) or 600 mg/m² (n = 4) for 3 doses. The majority of clinicians (n = 14) gave repeated IVMP (variable intervals/duration). 17/18 reported using oral prednisolone in addition to the IVMP, the most widely used doses being 60 mg/m² (n = 5) or 1-2 mg/kg (n = 5). Weaning regime was described by 4 units using tapering courses including reduction in BILAG, biomarkers, & physician’s clinical assessment. Weaning regimes varied between all units. Ten units reported routine use of maintenance steroids; the dose range was usually 5-10 mg. Personal experience was the main rationale for treatment decisions.

Management of Disease Flare (to BILAG A):
In the treatment of flare of JSLE, 15 units reported using pulsed IVMP; 10 units also increased oral prednisolone doses; 3 reported increasing oral prednisolone dose alone. IVMP doses for flare were similar to those for induction of remission at diagnosis, as was the weaning regime of oral prednisolone (wide variance noted between clinicians) and use of maintenance steroids.

Conclusions: Steroid prescribing for acute JSLE varied widely between and within units. As part of the UK JSLE Study Group, with an emerging clinical trials agenda, it is vital to accrue an evidence base to direct steroid prescribing in the management of JSLE acute presentation and flare. With paucity of evidence from the literature, expert opinion (category D evidence) forms the main basis for current treatment. We aim to carry this research forward and clinical trials to guide steroid use in this setting are in development.

Disclosure: The authors have declared no conflicts of interest.

90. PAIN AND QUALITY OF LIFE PERCEPTION IN CHILDREN WITH HYPERMOBILITY SYNDROME
Francis Fatoye1, Shea Palmer2, Fiona Macmillan3, Philip Rowe4 and Marietta Van der Linden4
1Departmental Registration Department, Manchester Metropolitan University, Manchester, United Kingdom, 2School of Health & Social Care, University of the West of England, Bristol, United Kingdom, 3School of Health Sciences, Queen Margaret University, Edinburgh, United Kingdom and 4Bioengineering Unit, University of Strathclyde, Glasgow, United Kingdom

Background: Hypermobility syndrome (HMS) is a major source of morbidity in childhood, with pain being a predominant symptom. As part of the UK JSLE Study Group, with an emerging clinical trials agenda, it is vital to accrue an evidence base to direct steroid prescribing in the management of JSLE acute presentation and flare. With paucity of evidence from the literature, expert opinion (category D evidence) forms the main basis for current treatment. We aim to carry this research forward and clinical trials to guide steroid use in this setting are in development.

Disclosure: The authors have declared no conflicts of interest.

Downloaded from http://rheumatology.oxfordjournals.org/ on December 19, 2012 by Queens University of Belfast